Modernizing API Oversight: The regulatory environment for Active Pharmaceutical Ingredients (APIs) is shifting rapidly to keep pace with innovation in the global pharmaceutical sector.
FDA Strategic Priorities: Current FDA guidance is centered on five pillars: patient-centricity (RWE), biomarker research, AI and predictive modeling, advanced manufacturing, and data integrity.
Risk-Based Compliance: Regulatory bodies are adopting a rigorous risk-based approach to oversight, placing increased scrutiny on the quality systems of third-party manufacturers (CDMOs).
Global Regulatory Harmonization: To reduce market fragmentation, the International Council for Harmonisation (ICH) is leading efforts to standardize API quality and safety requirements worldwide.
Digital Transformation: The integration of AI and computer modeling is no longer optional; it is now a core focus for the FDA in streamlining drug development and manufacturing efficiency.
1 The New Normal
1.1 The regulatory landscape for APIs is undergoing significant transformation, mirroring the intricacies of a rapidly evolving pharmaceutical sector. These regulatory shifts are not just a reflection of technological and scientific advancements, but also a response to the changing global dynamics and emergent challenges in healthcare.
1.2 The dramatic advances in the genetic, molecular, biologic, and pharmaceutical sciences in recent years have created challenges for regulatory agencies. The FDA, recognizing the need for concomitant advances in regulatory science, published the report Advancing Regulatory Science at FDA: Focus Areas of Regulatory Science (FARS) in early 2021.[1] The focus areas cross major FDA Strategic Initiatives, including Public Health Preparedness and Response, Increasing Choice and Competition through Innovation, Unleashing the Power of Data, and Empowering Patients and Consumers.[2]
1.3 Five of the main topics include patient centricity and real-world evidence, biomarker research, AI and computer modeling, advanced manufacturing (additive manufacturing / 3D printing, continuous processing, modularization, “smart” manufacturing), and the power of data.[2] By focusing on these areas, the FDA intends to provide meaningful regulatory insight on new and emerging approaches to drug development and governance.
1.4 The COVID-19 pandemic introduced an additional layer of complexity and created a whole new set of challenges for the regulation of drug development and manufacturing. It also clearly demonstrated the need for regulatory flexibility to improve synergies through better collaboration and the incorporation of risk-based approaches without dropping standards or compromising GMP compliance.[3] Several temporary emergency accommodations were issued to maintain supply and accelerate the development of new therapies.[4] Some of these measures have already become permanent, and others are likely to do so.
1.5 One example is remote inspections, which offer efficiency benefits. Technology is available today that can intrinsically make it easier to complete assessments, such as electronic document sharing and review, collaborative teleconferencing, and livestreaming of onsite video. These technologies align well with the overall trend toward digitalization and the FDA’s Industry 4.0 initiative.[3]
1.6 The FDA has issued guidance[5] in response to a section in the CARES Act that requires registrants of drug establishments (or their authorized agents) to submit annual reports on the amount of each listed drug that is manufactured, prepared, propagated, compounded, or processed for commercial distribution.[6]
1.7 This additional reporting expectation is just one example of the increasing regulatory requirements that are collectively having a strong impact on pharmaceutical manufacturing.[7] A 2021 PricewaterhouseCoopers global survey of pharmaceutical CEOs found that changes in industry regulations are considered one of the top three disruptive business trends that they face.[8]
1.8 Meanwhile, digitalization is making it easier for API manufacturers to comply with regulatory requirements. Data are recorded automatically and more accessibly. They can be readily shared, compiled, and analyzed. Systems can be put in place to ensure security, traceability, and incorruptibility. Automation combined with digitalization helps reduce the risk of human error and generally results in more consistent product of higher quality. Specific digital tools that can help facilitate regulatory compliance include natural language processing, AI, and cloud computing.
1.9 Other activities at the FDA have been focused on facilitating the development of generic drugs, pediatric therapies, oncology treatments, and medicines for rare diseases, as well as encouraging the development of novel antimicrobials and antiviral drugs (including HIV treatments) and increasing the efficiency of the drug development process in general.
1.10 Finally, it should be noted that if the recommendations of the NASEM expert committee for addressing the most significant root causes of medical product shortages are implemented,[9] the reporting burden for API manufacturers will increase significantly.
2 Regulation of third-party manufacturers
2.1 As the pharmaceutical industry leans more into outsourcing, regulations are adapting to oversee this growing role of third- party manufacturers and suppliers. This includes stringent quality checks, regular audits, and ensuring that these external entities align with the regulatory expectations set for in-house manufacturing units.
2.2 To help provide a more predictable and efficient approach to management of post-approval changes, the agency issued a final guidance for industry with new ICH guidelines in May 2021.[10] It has also initiated two quality management maturity (QMM) pilot programs: one for domestic sites for finished dosage form (FDF) manufacturers and another for foreign sites for API manufacturers.[11] The intent of QMM ratings is to help establish and maintain consistent, reliable, and robust business processes to achieve quality policies and objectives, and to ensure continuous improvement, which is necessary if the FDA’s modern pharmaceutical quality vision is to be realized, according to Acting Commissioner Janet Woodcock. They will also allow the agency to identify which manufacturing sites go above and beyond the minimum practices required by cGMP regulations.
3 Risk-based oversight
3.1 Against the challenges listed above, risk-based oversight is also becoming an increasingly common approach to accommodate a dynamic regulatory environment. Instead of a one-size-fits- all approach, regulatory bodies are leaning towards a model that allocates resources and scrutiny based on the perceived risk of the API or the manufacturing process. This ensures that high-risk entities receive appropriate attention, optimizing the regulatory process.
4 Patient-centric regulations
4.1 A more patient-centric attitude toward regulation is a notable trend receiving emphasis in the wake of rising patient advocacy. Regulatory decisions are increasingly being made with the patient's well-being at the core. This involves faster approvals for critical drugs, stringent post- market surveillance, and fostering an environment where patient feedback directly influences regulatory decisions.
5 Supply Chains
5.1 The vulnerabilities of global supply chains, especially laid bare during events like the COVID-19 pandemic, have pushed regulatory bodies to mandate greater transparency and robustness in sourcing and distribution processes. There's a growing emphasis on diversification, reducing reliance on single-source suppliers, and promoting practices like dual-sourcing for critical raw materials.
5.2 Supply chains are also being rigorously reviewed by regulatory agencies in the United States and Europe, to increase security of supply and to reduce reliance on foreign manufacturers.[4] However, for manufacturers wishing to shift production to more local sites, the extensive validation and other compliance requirements have not been diminished. The FDA and EMA have also proposed specific plans for mitigating shortages of drug products and medical devices in the future. The FDA’s plans include longer expiration dates, requirement for application holders of certain drugs to conduct periodic risk assessments, and stronger data-sharing requirements.
6 Regulatory Harmonization
6.1 Harmonization of regulatory standards is at the forefront. Recognizing the interconnectedness of the global pharmaceutical market, regulatory bodies are striving for a unified set of guidelines and standards. Organizations, such as the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), are leading this endeavor by simplifying approval processes and fostering global cooperation among regulatory entities. This not only facilitates smoother market access for new APIs but also ensures consistent quality standards across regions, ensuring patient safety and trust.
6.2. Harmonizing regulatory standards is paramount for international pharmaceutical trade. Regulatory bodies worldwide, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), are working tirelessly to align quality, safety, and efficacy standards. This alignment simplifies the process of obtaining approvals for new APIs, expediting drug development. It also fosters global cooperation among regulatory agencies. The pharmaceutical industry benefits from reduced duplication of efforts and faster market access. As this trend progresses, it not only streamlines the path to market but also encourages consistent quality standards across regions, ultimately benefiting patients and healthcare systems worldwide.
6.3 There remains a need for greater harmonization across vendors so that data sharing can be increased within and across organizations.[8] Wider adoption of advanced data management technologies across all operations, from commercial compliance to regulatory, quality, and safety functions, is necessary. Greater investment in automation and more transparency between different groups within companies are essential to reduce data silos. Small pharmaceutical companies also require additional resources to be able to stay current and comply with rapidly evolving regulations. To support the effective and efficient use of data in the pharmaceutical industry, the FDA formed the Office of Digital Transformation, reorganizing its IT, data, and cybersecurity functions to the agency level.[12]
6.4 In essence, the regulatory panorama for APIs is evolving into a more holistic, global, and risk- focused framework. While the challenges are manifold, these trends signify a concerted effort to ensure the highest standards of patient safety, efficacy, and trust in the pharmaceutical realm.
FAQs:
How is the FDA modernizing the regulation of Small Molecule APIs?
The FDA is modernizing Small Molecule API regulation by implementing the Focus Areas of Regulatory Science (FARS), which emphasizes AI, computer modeling, and advanced manufacturing. This shift moves the agency toward a risk-based approach for oversight, utilizing digitalization and remote inspections to improve the efficiency of drug substance evaluations.
What is the role of Quality Management Maturity (QMM) in API manufacturing?
Quality Management Maturity (QMM) ratings are FDA pilot programs designed to identify API manufacturing sites that exceed minimum cGMP regulations. These ratings help establish robust business processes and ensure continuous improvement, which is vital for achieving the FDA’s modern pharmaceutical quality vision and ensuring a reliable drug supply.
How has the COVID-19 pandemic impacted API regulatory requirements?
The COVID-19 pandemic accelerated regulatory flexibility and the adoption of remote inspections through electronic document sharing and livestreaming. It also exposed supply chain vulnerabilities, leading to new mandates for diversification, dual-sourcing of raw materials, and stricter data-sharing requirements to prevent future drug shortages.
Why is regulatory harmonization critical for the global API market?
Regulatory harmonization is paramount because it aligns quality, safety, and efficacy standards across different regions through organizations like the ICH. This alignment simplifies the API approval process, reduces the duplication of efforts for manufacturers, and ensures consistent quality standards, ultimately expediting drug development and improving global patient safety.
What reporting changes are required under the CARES Act for drug manufacturers?
Under the CARES Act, drug establishment registrants must submit annual reports detailing the specific amounts of each listed drug manufactured for commercial distribution. These reporting expectations are part of a broader trend toward increasing regulatory requirements aimed at improving supply chain transparency and addressing the root causes of medical product shortages.
